Close Menu

NEW YORK – Caris Life Sciences has detailed the development and validation of its AI-driven tumor origin predictor, MI GPSai, which the firm has been offering clinically since December 2019 to help direct treatment for patients with carcinoma of unknown primary (metastatic cancer that has no clear origin) and, in certain cases, to inform physicians of possible cases of non-CUP misdiagnosis.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.